Why Is AstraZeneca plc Still Trading At A Premium To GlaxoSmithKline plc?

Roland Head asks why AstraZeneca plc (LON:AZN) continues to trade at a premium to GlaxoSmithKline plc (LON:GSK), following the failed Pfizer takeover bid.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The dust has now settled on Pfizer’s failed attempt to takeover AstraZeneca (LSE: AZN) (NYSE: AZN.US), but at 4,340p, the UK firm’s share price remains at a 14% premium to its pre-bid level of around 3,800p.

AstraZenecaWhat’s more, AstraZeneca’s forecast P/E of 17.5 puts it at a premium to its UK peer GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), which trades on a forecast 2014 P/E of just 15.

Why is AstraZeneca’s valuation still so high?

One explanation could be that the market is pricing in a repeat visit from Pfizer later this year, after the six-month wait period has expired. That’s possible, although it’s hard to see the logic — political will in the UK and US is likely to remain against Pfizer, and unless the US firm offers more money, the end result is likely to be the same.

Should you invest £1,000 in Ithaca Energy right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Ithaca Energy made the list?

See the 6 stocks

A second possible explanation could be that Pfizer’s advances have forced AstraZeneca to reveal new information about its product pipeline that have materially increased its valuation.

However, while it’s certainly true that AstraZeneca has embarked on a major PR offensive to talk up its sales prospects, nothing material seems to have changed. Analysts’ consensus earnings forecasts for the next couple of years have actually edged lower over the last month.

In contrast, during the same period, Glaxo has sold its portfolio of oncology drugs to Swiss pharma firm Novartis for $16bn, announced a £4bn capital return to shareholders and spent $5.25bn on acquiring a portfolio of vaccines that should help it consolidate its dominant position in this sector.

Most recently, Glaxo has announced a new oncology joint venture that could result in a further lucrative spin-off in years to come.

What about fundamentals?

I’ve already touched on AstraZeneca’s premium P/E rating, but a closer look at the firm’s financials reveals several even less appealing figures:

  AstraZeneca GlaxoSmithKline
Return on Capital Employed (ROCE) 8.0% 24.7%
Operating margin 14.4% 26.5%
Prospective yield 3.9% 5.2%

Source: Company reports, Reuters consensus forecasts

For the record, I believe AstraZeneca is a great company and will deliver solid long-term returns to shareholders — but so is GlaxoSmithKline, and Glaxo is currently delivering attractive returns to shareholders, such as the £4bn capital return planned for next year, which equates to around 82p per share.

AstraZeneca shares are up 32% on one year ago, while GlaxoSmithKline’s share price is down by 5%. I don’t think that’s a fair assessment of the two firms’ relative progress over that time, which is why I would buy Glaxo today, but not AstraZeneca.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but not in any of the other companies mentioned in this article. The Motley Fool has recommended shares in Glaxo.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

The 2025 stock market sell-off could be a rare opportunity for second income investors

Millions of Britons invest for a second income and many will be asking whether the current market conditions are a…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

The stock market in 2025 could be a once-in-a-decade opportunity to build wealth in an ISA

This writer sees further volatility ahead in the stock market, which should create lucrative opportunities for ISA investors.

Read more »

Google office headquarters
Investing Articles

$1bn a day! This S&P 500 share still looks like a stock market bargain after Q1 earnings

The owner of Google and YouTube just announced strong results to the stock market, including another massive $70bn share buyback.

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

3 cheap FTSE 100 stocks with big dividends to consider buying right now

Sector weakness in some FTSE 100 industries has also left some of my long-term favourite stocks offering attractive dividend yields.

Read more »

Diverse children studying outdoors
Growth Shares

Forecast: £1,000 invested in Rolls-Royce shares could be worth this much by next year

Jon Smith talks through both his opinion and analysts’ forecasts when trying to predict where Rolls-Royce shares could head from…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

£5,000 invested in Lloyds shares 5 years ago is now worth…

The price of Lloyds shares has more than doubled over the past five years. However, our writer’s cautious about the…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Up 58% in a year, the BT share price could be the FTSE 100 target to beat in 2025

The BT share price has been steadily climbing back since newish boss Allison Kirkby came on board. Is the new…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£10,000 invested in Nvidia stock 5 years ago is now worth…

Even after the Nvidia stock falls of the past couple of months, its five-year performance remains stunning. And it could…

Read more »